AVTE — Aerovate Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $606.02m
- $483.58m
- 19
- 15
- 84
- 34
Annual cashflow statement for Aerovate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.33 | -9.61 | -23 | -51.5 | -75.5 |
| Depreciation | |||||
| Non-Cash Items | 0 | 0.777 | 2.06 | 4.57 | 8.85 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.549 | 0.974 | -6.51 | 7.75 | 9.8 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.78 | -7.86 | -27.4 | -39.1 | -56.8 |
| Capital Expenditures | — | — | -0.181 | -0.195 | -0.142 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -113 | 7.12 | 12 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | — | -113 | 6.93 | 11.9 |
| Financing Cash Flow Items | — | — | — | -0.371 | -0.234 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.5 | 8.92 | 190 | 0.396 | 46 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.281 | 1.06 | 49.6 | -31.8 | 1.09 |